【摘要】 目的　观察重组人表皮生长因子 (rhEGF)用于深Ⅱ度烧伤创面治疗的远期疗效及安全性。　方法　对 37例烧伤患者进行随机、双盲、同体对照实验 ,每例患者选择一块深Ⅱ度烧伤创面 ,并将其分为面积相近的两部分 ,于伤后第 1天开始分别用单纯等渗盐水 (对照组 )和含rhEGF的等渗盐水 (治疗组 )进行换药治疗。创面愈合后 1、4年时 ,对各患者进行院外随访 ,采用改良温哥华瘢痕测量法 ,评价上述受试创面愈合后的瘢痕指数 (SI)。　结果　 1年后随访时 ,治疗组SI为 7.19± 1.6 7,明显小于对照组 8.92± 1.78(P <0 .0 1) ;4年后随访时 ,治疗组SI为 6 .12± 1.5 4 ,明显小于对照组 8.0 9± 1.81(P <0 .0 1)。所有受试创面均无肿瘤形成、癌变等并发症发生。　结论　外用rhEGF治疗深Ⅱ度烧伤创面 ,能明显减少后期瘢痕的形成 ,远期疗效和安全性较好。更多还原

【Abstract】 Objective To evaluate the safety and long-term effect of recombinant human epithelial growth factor (rhEGF) on deep partial-thickness burn wounds. Methods Thirty-seven burn patients were enrolled in this study and were observed by randomized, double-blinded and placebo-controlled protocol. An area of deep partial-thickness burn wounds from each patient was divided into control (C) and treatment (T) portions. The wound in C was treated with normal saline while that in T with rhEGF. The patients were followed-up for 1 and 4 years after wound healing. The healed wounds were evaluated by modified Vancouver scar scale in terms of scar index (SI). Results 1 year after wound healing, it was found that the SI in T group (7.19±1.67) was obviously lower than that in C group(8.92±1.78, P <0.01). The SI in T group (6.12±1.54) was still evidently lower than that in C group(8.09±1.81, P <0.01) four years after wound healing. There were no signs of development of tumor or cancer in all the tested burn wound areas. Conclusion External application of rhEGF might be beneficial to the healing quality of deep partial-thickness burn wound with less scar formation and better long-term effects, and it is safe.更多还原